deltatrials
Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01647880

MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (MOVING)

Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis

Sponsor: Charite University, Berlin, Germany

Conditions Multiple Sclerosis
Interventions Active Comparator receiving Extavia® Verum arm receiving Gilenya®
Updated 10 times since 2017 Last updated: Jul 28, 2021 Started: Jul 31, 2013 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

delayed recruitment

Other terminated trials from Charite University, Berlin, Germany

See all terminations from Charite University, Berlin, Germany

Other Multiple Sclerosis trials with similar outcome

Browse all Multiple Sclerosis trials

A PHASE2/PHASE3 clinical study on Multiple Sclerosis, this trial is terminated or withdrawn. The trial is conducted by Charite University, Berlin, Germany and has accumulated 10 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotTerminated~Aug 2017 – ~Jan 2018 · 5 months · monthly snapshotTerminated~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotTerminated~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotTerminated~Dec 2018 – ~May 2020 · 17 months · monthly snapshotTerminated~May 2020 – ~Jan 2021 · 8 months · monthly snapshotTerminated~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotTerminated~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Sep 2021 — Jul 2024 [monthly]

    Terminated PHASE2_PHASE3

  4. Jan 2021 — Sep 2021 [monthly]

    Terminated PHASE2_PHASE3

  5. May 2020 — Jan 2021 [monthly]

    Terminated PHASE2_PHASE3

▶ Show 5 earlier versions

  1. Dec 2018 — May 2020 [monthly]

    Terminated PHASE2_PHASE3

  2. Jun 2018 — Dec 2018 [monthly]

    Terminated PHASE2_PHASE3

  3. Jan 2018 — Jun 2018 [monthly]

    Terminated PHASE2_PHASE3

  4. Aug 2017 — Jan 2018 [monthly]

    Terminated PHASE2_PHASE3

  5. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE2_PHASE3

    First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Charite University, Berlin, Germany
  • NeuroCure Clinical Research Center, Charite, Berlin
Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations